# Advisory Committee for Pharmaceutical Science; Amendment of Notice
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Notice.
The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Advisory Committee for Pharmaceutical Science. This meeting was announced in the *Federal Register* of February 3, 2003 (68 FR 5297). The amendment is being made to reflect a change in the *Agenda* portion of the document. There are no other changes.
**FOR FURTHER INFORMATION CONTACT:**
Kathleen Reedy or LaNise Giles, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12539. Please call the Information Line for up-to-date information on this meeting.
**SUPPLEMENTARY INFORMATION:**
In the *Federal Register* of February 3, 2003 (68 FR 5297), FDA announced that a meeting of the Advisory Committee for Pharmaceutical Science would be held on March 12 and 13, 2003. On page 5298, in the first column, the second sentence in the *Agenda* portion of the document is amended to read as follows:
On March 13, 2003, the committee will: (1) Discuss and provide direction for future subcommittee: Pharmacology/Toxicology Subcommittee; (2) receive an update on the Office of Pharmaceutical Science research projects; (3) discuss and provide comments on dose content uniformity, parametric interval test for aerosol products; (4) discuss and provide comments on bioequivalence/bioavailability of endogenous drugs; and (5) discuss and provide comments on comparability protocols.
Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).
Dated: February 26, 2003.
William K. Hubbard,
Associate Commissioner for Policy and Planning.